| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S002280000206 |
| P8608 | Fatcat ID | release_u56z5hswnngvjpqntyf5qerhga |
| P698 | PubMed publication ID | 11214773 |
| P2093 | author name string | Andersson T | |
| Hassan-Alin M | |||
| Röhss K | |||
| Bredberg E | |||
| P433 | issue | 9-10 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| esomeprazole | Q553223 | ||
| P304 | page(s) | 665-670 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | |
| P478 | volume | 56 |
| Q55492457 | A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis. |
| Q42662159 | A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease |
| Q45172356 | A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects |
| Q46798229 | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication |
| Q91812497 | Analysis of the symptom response to esomeprazole 20 mg over days 1-4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials |
| Q90298395 | Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition |
| Q27005916 | CYP2C19 polymorphism influences Helicobacter pylori eradication |
| Q34509642 | Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor |
| Q35304679 | Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg |
| Q43107694 | Complexity in estimation of esomeprazole and its related impurities' stability in various stress conditions in low-dose aspirin and esomeprazole magnesium capsules |
| Q34618109 | Development and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma. |
| Q34340193 | Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole |
| Q34370499 | Dyspepsia: challenges in diagnosis and selection of treatment |
| Q36024697 | Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole |
| Q60952703 | Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients |
| Q34030127 | Esomeprazole |
| Q45045271 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms |
| Q42792216 | Esomeprazole for the treatment of peptic ulcer bleeding |
| Q37390644 | Esomeprazole: a proton pump inhibitor |
| Q34716982 | Esomeprazole: a review of its use in the management of acid-related disorders |
| Q34621465 | Esomeprazole: a review of its use in the management of acid-related disorders in the US. |
| Q37032564 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults |
| Q37755220 | Esomeprazole: potent acid suppression in the treatment of acid-related disorders |
| Q39412138 | Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis |
| Q83835375 | Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits |
| Q44826199 | Intravenous esomeprazole |
| Q37321407 | Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. |
| Q36174538 | Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders |
| Q46559957 | Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs |
| Q38030989 | Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. |
| Q34570478 | Pharmacokinetic drug interaction profiles of proton pump inhibitors |
| Q38229080 | Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease |
| Q34320782 | Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole |
| Q43564480 | Pharmacokinetic study of esomeprazole in the elderly |
| Q43742706 | Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole |
| Q64907175 | Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. |
| Q46858378 | Pharmacokinetics of esomeprazole following varying intravenous administration rates |
| Q36116456 | Pharmacokinetics of proton pump inhibitors in children |
| Q35558230 | Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. |
| Q35572512 | Pharmacologic properties of proton pump inhibitors |
| Q37018462 | Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors. |
| Q39240124 | Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions |
| Q33222162 | Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. |
| Q33224563 | Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. |
| Q35076637 | Review article: pharmacology of esomeprazole and comparisons with omeprazole |
| Q35058137 | Review of esomeprazole in the treatment of acid disorders |
| Q37605518 | Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report |
| Q39962737 | Simultaneous Estimation of Esomeprazole and Domperidone by UV Spectrophotometric Method. |
| Q35766743 | Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology |
| Q55266404 | Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials. |
| Q37552951 | The pharmacology of esomeprazole and its role in gastric acid related diseases |
| Q35660960 | The role of proton pump inhibitors in gastro-oesophageal reflux disease |
| Q35039109 | The use of proton pump inhibitors in children: a comprehensive review |
Search more.